Evaxion A/S stands at a point where the equity and the science have decoupled. The company is a clinical-stage vaccine developer whose lead asset is a personalized neoantigen cancer vaccine in a Phase 2 trial in advanced melanoma, and the two-year outcome data reported last autumn carried an objective response rate of 75 percent with four of the sixteen treated patients in complete response. The equity, however, trades at a market capitalization near $27 million against a cash balance of $14.0 million and a burn that has consumed roughly half the company's resources since the start of the year.
The load-bearing quarter is the second quarter 2026 print, which confirmed a net loss of $3.7 million. The runway that management extends is only into the second half of 2027. The single material event is the upcoming three-year data set due at the European Society for Medical Oncology congress in Madrid in late October 2026, the first read that separates the vaccine as a stand-alone therapy from its prior use in combination with an anti-PD-1 checkpoint inhibitor. The argument that follows is whether a pre-clinical-proof platform can still capture enough option value at this price to offset the dilution already embedded in the share count and the financing the company still has to run.